Nektar Therapeutics (NKTR) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Jefferies Raises Price Target on Nektar Therapeutics (NKTR) to $15
November 7, 2016 8:58 AM ESTJefferies reiterated a Buy on Nektar Therapeutics (NASDAQ: NKTR), and raised the price target to $15.00 (from $14.00), following the company's 3Q earnings report. Based on the recently completed equity offering and mgts updated guidance, Jefferies now estimates FY16 & FY17 revenues and EPS of $170M & ($1.17) and $284 & ($0.57) vs $188M &... More
